NMTC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMTC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. NeuroOne Medical Technologies's total current assets for the quarter that ended in Dec. 2024 was $5.71 Mil.
The historical data trend for NeuroOne Medical Technologies's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | Sep24 | |||||||||||
Total Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
4.16 | 7.29 | 12.18 | 7.31 | 4.63 |
NeuroOne Medical Technologies Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
5.09 | 4.71 | 4.09 | 4.63 | 5.71 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
NeuroOne Medical Technologies's Total Current Assets for the fiscal year that ended in Sep. 2024 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 1.46 | + | 0.177 | + | 2.635 | + | 0.359 | |
= | 4.63 |
NeuroOne Medical Technologies's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 1.134 | + | 2.369 | + | 1.931 | + | 0.278 | |
= | 5.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
NeuroOne Medical Technologies (NAS:NMTC) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
NeuroOne Medical Technologies's Liquidation Value for the quarter that ended in Dec. 2024 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 1.134 | - | 3.559 | + | 0.75 * 2.369 | + | 0.5 * 1.931 |
= | 0.32 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Ronald W. Mcclurg | officer: Chief Financial Officer | C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344 |
David A Rosa | director, officer: CEO and President | 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343 |
Mark Christianson | 10 percent owner, officer: VP, Business Dev and Marketing | 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
Hijaz Haris | officer: VP of Marketing | C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344 |
Morgan C. Frank | 10 percent owner | 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907 |
Manchester Management Co Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02110 |
Manchester Explorer, L.p. | 10 percent owner | MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114 |
James E Besser | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Manchester Management Pr, Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Edward Andrle | director | C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344 |
Wade Fredrickson | 10 percent owner | 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
Steve Mertens | officer: Chief Technology Officer | 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343 |
Scott Heuler | officer: Vice President of Sales | 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343 |
Paul Buckman | director | 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402 |
Suraj Kalia | director | 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
From GuruFocus
By Marketwired • 03-18-2025
By Marketwired • 03-18-2025
By Marketwired • 03-18-2025
By GuruFocus News • 04-04-2025
By Marketwired • 04-14-2025
By Marketwired • 04-04-2025
By Marketwired • 01-03-2025
By GuruFocus News • 02-13-2025
By GuruFocus News • 04-16-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.